A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Start Date
2/8/2024
Completion Date
4/30/2028
Summary
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Alisertib
Conditions
Locations
Southern Cancer Center
Daphne, Alabama 36526
United States
The Oncology Institute of Hope and Innovation
Long Beach, California 90805
United States
Rocky Mountain Cancer Centers
Lone Tree, Colorado 80124
United States
Georgetown Lombardi Cancer Center
Washington D.C., District of Columbia 20057
United States
Clermont Oncology Center
Clermont, Florida 64711
United States
The Oncology Institute of Hope and Innovation
Fort Lauderdale, Florida 33316
United States
Moffitt Cancer Center
Tampa, Florida 33612
United States
Illinois Cancer Specialists
Niles, Illinois 60714
United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana 46202
United States
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland 21201
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
United States
Dana Farber Cancer Institute
Boston, Massachusetts 02215
United States
Henry Ford Hospital
Detroit, Michigan 48202
United States
Minnesota Oncology Hematology
Burnsville, Minnesota 55337
United States
Nebraska Cancer Specialists
Grand Island, Nebraska 68803
United States
Oncology Hematology Care Clinical Trials
Cincinnati, Ohio 45226
United States
University Hospital - Cleveland Medical Center
Cleveland, Ohio 44106
United States
Cleveland Clinic
Cleveland, Ohio 44195
United States
Zangmeister Cancer Center
Columbus, Ohio 43219
United States
Oncology Associates of Oregon
Eugene, Oregon 97401
United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania 15232
United States
Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina 29425
United States
SCRI Oncology Partners
Nashville, Tennessee 37203
United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas 75246
United States
University of Texas Southwestern Medical Center
Dallas, Texas 75390
United States
Oncology & Hematology Associates of Southwest Virginia
Blacksburg, Virginia 24073
United States
Universtity of Virginia Health System
Charlottesville, Virginia 22908
United States
Virginia Cancer Specialists Research Institute
Fairfax, Virginia 22031
United States
Northwest Cancer Specialists
Vancouver, Washington 98686
United States
Marshfield Medical Center
Marshfield, Wisconsin 54449
United States